Jinan Carbotang Biotech Co., Ltd. is a joint venture between Jinan Shengquan Group Co., Ltd. and British cabosens Co., Ltd. established in 2010. It is mainly committed to the R & D, production and sales of sugars, nucleosides and other pharmaceutical intermediates and APIs. The company has professional production, testing and R & D equipment, high-level R & D team and complete production R & D management system. Since its establishment in 2011, Jinan Shangbo Pharmaceutical Research Institute has formed a high-level R & D team of more than 40, including 3 doctors and 10 masters. Over the years, the R & D team has worked with many famous universities and research institutes at home and abroad, such as Oxford University, Moscow State University, Latvian Institute of organic chemistry, Shanghai Fudan University, Shanghai Institute of organic chemistry The Institute of chemistry of the Chinese Academy of Sciences has carried out extensive cooperation in various forms and successfully developed a number of pharmaceutical R & D projects with independent intellectual property rights. At present, more than 200 projects have been successfully developed by the Pharmaceutical Research Institute, and more than 100 projects have been successfully industrialized in the workshop. In 2015, our company invested more than 60 million yuan to build a new cGMP workshop, which was designed and built under the full guidance of foreign experts and fully met the requirements of the drug review departments of the European Union, the United States and China. The workshop has excellent equipment and complete public facilities. It is equipped with 35 reactors of various specifications from 160l-3m3, film evaporator, centrifuge, vacuum drying equipment and other common reaction and separation equipment. There are also four standard workshops with lean packages, which can meet the customized processing of products from kilogram to ton. The workshop is also equipped with tail gas absorption devices, It can absorb the process tail gas and unorganized exhaust gas produced by the workshop. At the end of 2017, the high-pressure hydrogenation workshop built by the company with an investment of more than 20 million yuan was completed and can be put into production in 2018, further improving the company's ability to carry out production transformation in the cdmo market. At the same time, relying on the large-scale sewage treatment device and solid waste incineration device invested by the parent company Jinan Shengquan group, the company can better undertake a variety of products and projects of different scales at home and abroad in accordance with the requirements of environmental protection. Jinan Shangbo Biotechnology Co., Ltd. will continue to cooperate with domestic and foreign pharmaceutical enterprises with diversified cooperation modes, and occupy a leading position in the cdmo field of advanced pharmaceutical intermediates and APIs.